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Abstract 
Purpose: As the breast cancer survivor population increases, the topic of screening these women for recurrences 
is increasingly relevant. In our institution, we use both breast MRI and mammography in the surveillance of breast 
cancer survivors, although little data exists on the use of MRI in this setting. We present a retrospective analysis of our 
experience and compare the sensitivity and specificity of MRI vs. mammography in this setting.
Methods: We identified women under 65 with a history of breast cancer and at least one follow-up MRI performed 
along with a mammogram done within 6 months of the MRI. We compared the outcomes of MRI and mammography 
in terms of biopsies performed as well as in detection of new cancers.
Results: Of 617 charts reviewed, 249 patients met inclusion criteria, with 571 paired MRI/mammogram results. There 
were 27 biopsies performed due to MRI findings alone, 10 done due to mammographic findings alone, and 15 done 
based on abnormalities seen on both imaging modalities. There were 8 malignancies identified based on an abnor-
mal MRI, 3 detected on both MRI and mammography, and none identified via mammography alone. Overall, MRI 
had a sensitivity of 84.6% (the 95% CI 54.6–98.1) and a specificity of 95.3% (the 95% CI 93.3–96.9); mammography a 
sensitivity of 23.1% (the 95% CI 5.0–53.8), and a specificity of 96.4% (the 95% CI 94.5–97.8).
Conclusions: Breast MRI is a useful surveillance modality in breast cancer survivors and may be more sensitive at 
detecting recurrences than mammography alone in this population.
Keywords: Breast cancer, Magnetic resonance imaging, Bilateral, Surveillance
© 2015 Weinstock et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Breast cancer remains one of the most common cancers 
affecting women in the United States, with an annual 
incidence of approximately 232,670 cases forecasted for 
2014. As early diagnosis rates and treatments improve, 
the breast cancer survivor population continues to 
increase, with an estimated 2.9 million women in the US 
currently alive with a personal history of breast cancer 
(2014). The question of how to best follow these patients 
once they have completed therapy for their initial breast 
cancers is becoming increasingly relevant.
Women with a history of breast cancer are known to 
face a higher risk of developing new or recurrent disease. 
Estimated risk of contralateral tumor development in 
breast cancer survivors who have completed initial ther-
apy and have not undergone prophylactic contralateral 
mastectomy is approximately 0.5% per year and is not 
dependent on age of diagnosis or time since diagnosis 
(Chen et al. 1999), although there is some evidence that 
this risk is decreasing in the era of modern systemic ther-
apy (Nichols et al. 2011).
At this point there remains much controversy regard-
ing the optimal imaging modality to use in surveillance of 
these women for the development of contralateral breast 
cancers or of in-breast recurrences. Current guidelines 
published by the American Society of Clinical Oncology 
recommend mammography alone as an imaging modal-
ity suitable for surveillance of these patients; this is simi-
lar to the recommendation for the use of mammogram 
in the routine surveillance of unaffected women over 50. 
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No other imaging modality, including breast magnetic 
resonance imaging (MRI), was thought to have sufficient 
evidence to justify inclusion in the recommended sur-
veillance of breast cancer survivors (Khatcheressian et al. 
2012). NCCN guidelines similarly recommend annual 
mammography as the mainstay of surveillance for these 
patients (2014).
When stating that MRI is not recommended in surveil-
lance of breast cancer survivors it is useful to examine 
the evidence base for the use of the recommended sur-
veillance mode, i.e. mammography. In actuality, there is 
no randomized clinical trial that examines the impact on 
breast cancer mortality achieved via the use of annual 
mammography, as recommended, in breast cancer sur-
vivors. While there is some suggestion of benefit based 
on systematic review of small data sets (Robertson et al. 
2011), the use of mammography in the breast cancer sur-
vivor cohort is partially based on extrapolation of likely 
benefit from trials of population screening which have 
demonstrated a reduction breast cancer mortality (Hous-
sami and Ciatto 2010).
Extrapolating data on benefit from population stud-
ies is problematic since breast cancer survivors may 
differ in several important ways from the population 
at large. Namely, breast cancer survivors tend to be 
younger, with approximately 20% of all new cases in the 
U.S. diagnosed in women under 50 (2014). In most pri-
mary screening studies, the reduction in mortality con-
ferred by screening mammography was less for women 
ages 40–49 than for women over age 50 (Humphrey 
et al. 2002). Young women tend to have dense breasts, 
thus decreasing mammographic sensitivity (Wolfe 
1976; Carney et  al. 2003). Additionally, risk factors 
that played a role in the development of first cancers, 
whether they are environmental or genetic or a com-
bination of the two, are still relevant in raising the risk 
that breast cancer survivors face in developing new or 
recurrent cancers. There are also risks of local recur-
rence of treated breast tumors that the general popula-
tion does not face.
For all of the above reasons, breast cancer survivors 
tend to be at a higher baseline risk of tumor occurrence, 
and screening recommendations that apply to the gen-
eral population may not be adequate. In fact, system-
atic review of the literature in the retrospective setting 
indicates that when recurrent or new breast cancers are 
detected in patients who have a history of breast can-
cer, they may be detected via methods other than mam-
mography. Previous studies have reported that 50–72% 
of ipsilateral recurrences (Orel et  al. 1992; Grosse et  al. 
1997; Ashkanani et  al. 2001; Joseph et  al. 1998) and 
37–80% of contralateral new primaries (de la Roche-
fordière et al. 1996; Kollias et al. 2000; Hill-Kayser et al. 
2006; Robinson et  al. 2007; Weinstock et  al. 2012) are 
mammographically-detected.
The empiric use of MRI as an adjunct to mammogra-
phy for surveillance of breast cancer survivors (Wer-
nli et  al. 2014) is also an extrapolation, based on data 
obtained via the use of this imaging modality in other 
high-risk patient populations, such as in the screening of 
BRCA1 and BRCA2 mutation carriers (Kuhl et al. 2005; 
Warner et al. 2004; Kriege et al. 2004; Leach et al. 2005; 
Lehman et al. 2005). In this setting, MRI has proven to be 
useful in detecting what appear to mammographically-
occult cancers, and is in fact recommended for routine 
screening of these patients as a result (2014). There is 
data demonstrating clinical utility and high cancer detec-
tion rate in the use of MRI in this setting in a formalized, 
population-based screening program (Chiarelli et  al. 
2014). Conversely, there has been recent evidence that 
the use of MRI in another setting; i.e. in the preoperative 
imaging of the affected and contralateral breast in newly-
diagnosed patients, may be less useful than originally 
thought in terms of its effect on local or distal recurrence 
risks (Houssami et al. 2014).
In view of the uncertainty of the utility of breast MRI in 
those with a personal history of breast cancer, and in light 
of the paucity of published data on what is becoming an 
ever-enlarging cohort of patients, we felt that a review of 
our institutional data would be useful to add to the litera-
ture on the subject. At our institution we have been using 
MRI since 2005 as an adjunct to mammography in sur-
veillance of these patients. We therefore present a review 
of our experience at the University of Maryland Medi-
cal Center in the use of MRI in screening women with 
a personal history of breast cancer. Our study aimed to 
compare the detection rate of ipsilateral recurrences and/
or of contralateral new primaries in breast cancer survi-
vors under 65 screened at our institution using MRI as 
an adjunct to mammography. We also aimed to compare 
the false-positive rate of surveillance MRI in this cohort 
to that of mammography, as well as to determine the rate 
of additional biopsies necessitated by the addition of MRI 
to routine mammography.
Methods
After approval was obtained by the institutional review 
board, we identified all consecutive breast MRIs per-
formed at the University of Maryland Medical Center 
from January 1, 2005 through December 31, 2011. We 
used chart reviews of electronic medical records for each 
patient with a history of breast cancer to retrospectively 
identify asymptomatic breast cancer survivors imaged 
with breast MRI within 6 months of a mammogram,. We 
excluded MRIs done at presentation or within 11 months 
of initial cancer diagnosis. We excluded patients with 
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stage IV disease and patients with imaging performed for 
diagnostic purposes for abnormal clinical findings. Addi-
tionally excluded were patients who had undergone bilat-
eral mastectomy and those who were known BRCA1 or 
BRCA2 mutation carriers. Lastly, we excluded all MRIs 
done on those with a history of high-risk breast lesions 
only, such as lobular carcinoma in situ (LCIS), and stud-
ies done on patients above age 65. Male patients were 
also excluded.
Once appropriate MRI/mammography pairs were 
identified, we conducted a chart review of the elec-
tronic medical records of identified patients to further 
obtain clinical data. Patient’s on-study characteristics 
included patient age, race, stage at original diagnosis, as 
well as type of original surgery performed (mastectomy 
vs. lumpectomy), TNM stage of original tumor, and ER/
PR and Her-2 status of original tumors. We then looked 
at data on each MRI and mammography performed in 
follow-up for each patient and recorded data on the date 
of each study and the Breast Imaging Reporting and Data 
System (BI-RADS) (D’Orsi et  al. 2003) score assigned 
each study by the reading radiologist.
All mammograms were performed on Hologic equip-
ment, which was digital after 2007, and included initial 
standard CC and MLO views of each breast or the uni-
lateral remaining breast if the patient had unilateral mas-
tectomy without reconstruction. All mammograms were 
performed on equipment accredited by the America Col-
lege of Radiology and meets the requirements for tech-
nical parameters and image quality mandated by the 
Mammography Quality Standard Act of the Food and 
Drug Administration. All mammograms were interpreted 
by a fellowship trained breast imager with 2–10 years of 
experience. Additional supplemental views and/or ultra-
sounds were performed for as deemed appropriate by the 
interpreting radiologists.
Breast MRI was performed on a 1.5 or 3 T commer-
cially available system (Siemens) using a dedicated sur-
face breast coil. The breast MRI protocol included a 
localizing sequence followed by an axial T1 nonfat sup-
pressed sequence (TR = 7 ms, TE = 2.5 ms) and an axial 
STIR sequence (TR =  4000 ms, TE =  43 ms). Contrast 
enhanced dynamic imaging included a series of axial 
gradient echo T1 with fat suppression obtained prior 
to and following intravenous administration of gado-
linium contrast. The three post-contrast dynamic series 
were obtained at 1, 2, and 6  min. Between the second 
and third time points, an additional high resolution 
axial T1 with fat suppression was acquired. The dynamic 
sequence used TR, 3.9 ms; TE, 1.8 ms; and a flip angle, 
10°, slice thickness of 1.2  mm with no gap, a matrix of 
448 ×  358; and a field of view of 32–40  cm depending 
on the breast size. Sequence acquisition time was 1 min 
and 2 s. The high resolution interview sequence used TR, 
4.1 ms; TE, 1.9 ms; and flip angle, 10°, slice thickness of 
0.8 mm with no gap, a matrix of 448 × 448, and a field 
of view of 32–40  cm depending on the breast size, the 
sequence acquisition time was 3 min and 1 s. Unilateral 
sagittal T2 W series of the right and left breast were also 
obtained. Total imaging time was approximately 30 min.
Post-processing included Maximum Intensity Projec-
tion (MIP) with and without subtraction, and subtracted 
images obtained by subtracting the dynamic series of 
theunenhanced images from the first post-contrast. 
Interpretation was supplemented with Dynacad and 
Aegis Sentinel software prior to and after 2010, respec-
tively, for further characterization of lesion kinetics.
We reviewed imaging reports for the negative MRIs 
and mammograms, and BI-RADS score was recorded for 
each study. Cases with suspicious imaging findings which 
led to biopsy were retrospectively reviewed in blinded 
fashion by a fellowship trained breast imager with greater 
than 10  years of experience. The side, location, number 
and features of the suspicious imaging findings were 
recorded according to BI-RADS lexicon. In addition to 
the breast findings, axillary and extramammary findings 
were recorded.
Biopsies of BI-RADS 4 and 5 MRIs were performed 
by a board certified fellowship trained breast radiolo-
gist via imaging guided biopsy or by a board certified 
breast surgeon. The biopsy modality and whether ipsi-
lateral or contralateral to the side of initial breast cancer 
was recorded for every biopsied lesion. Pathology was 
reviewed by a board certified pathologist and results 
were recorded. For malignancies, histology, grade, and 
staging were recorded. After determining the total num-
ber of benign, high risk, and malignant biopsy results, 
these results were correlated with whether the suspicious 
findings were detected on MRI, mammogram, or both. In 
case of ambiguity, review of pathological specimens was 
retrospectively undertaken by a breast pathologist. Inter-
val cancers detected by physical exam in patients with 
negative imaging were also recorded.
Once the above data was collected for each patient, 
sensitivity and specificity were calculated for each modal-
ity; mammogram and MRI individually, as well as mam-
mogram combined with MRI. For patients with more 
than one biopsy, which resulted from a single positive 
MRI/mammogram pair, all of the biopsies were included 
in the analysis. For patients with more than one posi-
tive MRI/mammogram pair, the second set of exams in 
the subsequent years and any resulting biopsies were 
excluded from the analysis so as not to over-represent 
any single patient in the sample. We then compared the 
outcome of MRI and mammography in terms of biopsies 
performed as well as in detection of new cancers.
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The following definitions were used for study param-
eters: True positive (TP) scans were those in which a 
breast lesion was histologically proven to be an inva-
sive breast cancer or a ductal carcinoma in situ (DCIS). 
True negative (TN) scans were those without a suspi-
cious lesion seen on imaging and no breast cancer was 
diagnosed in the next 12  months. False negative (FN) 
scans were those that did not detect a suspicious breast 
lesion, but a breast cancer was detected in the follow-
ing 12  months. False positive (FP) scans were those 
that resulted in biopsy that was subsequently benign. 
Sensitivity (Se) was defined as TPR = TP/(TP + FN), 
and specificity (Sp) was defined as TNR  =  TN/
(TN + FP).
Results
Of 617 consecutive charts reviewed for patients who 
underwent MRI at the University of Maryland between 
2005 and 2011, 249 patients met inclusion criteria, 124 
(49.6%) of whom were African-American. Patient charac-
teristics are presented in Table 1. There were 368 patients 
found ineligible for study inclusion. Reasons for exclusion 
are presented in Table 2. There were a total of 571 paired 
MRI/mammogram results included in our analysis; a 
median of 2.29 per patient (range 1–6). There were 52 
biopsies performed in 43 of the 249 patients in the study 
(17%) as a result of abnormalities detected on imaging.
Overall, 11 patients were diagnosed with malignancy. 
All 11 malignancies were seen on MRI and 3 were also 
seen on mammogram. No cancers were detected via 
mammography alone. Biopsies were done based on 
abnormalities detected on both MRI and mammography 
in 15 cases; 20% were malignant (n = 3). There were 27 
biopsies done based on abnormalities detected on MRI 
alone; 30% of the results (n = 8) were malignant. These 
8 cancers were detected based on MRI findings and were 
mammographically occult. There were 10 biopsies per-
formed based on abnormalities detected via mammogra-
phy alone; the results of all of these biopsies were benign.
The results of the abnormal imaging findings included 
47 breast lesions, 4 abnormal axillary lymph nodes, 
and 1 lung mass. Pathology was obtained in these cases 
using imaging-guided core needle biopsy (n =  30) and/
or surgical biopsy (n  =  22). Twelve malignant lesions 
were detected in 11 of 249 patients overall, at a rate of 
4.4%. The 11 cancers detected are described in Table  3, 
and included 10 breast cancers, 1 metastatic axillary 
lymph node and 1 isolated lung metastasis. One patient 
had two in-breast lesions simultaneously detected on the 
same MRI. Overall, 92% of recurrences were early-stage 
(Stage 0 or Stage I) disease. Of the 10 in-breast lesions, 
50% (n = 5) were ipsilateral recurrences in patients who 
had undergone breast-conserving therapy (n  =  3) or 
mastectomy (n =  2) and 50% (n =  5) represented con-
tralateral new primaries in patients with prior breast con-
serving therapy (n = 2) or mastectomy (n = 3).
Table 1 Patients’ on-study characteristics (N = 249)
Ethnicity N %
Caucasian 110 44.2
African American 123 49.4








 Female 249 100.0
Surgery
 Lumpectomy 137 55.0
 Mastectomy 109 43.4
Unknown 4 1.6
Chemotherapy
 Yes 135 54.2
 No 97 39.0
Unknown 17 6.8
Radiation
 Yes 157 63.1
 No 78 31.3
 Unknown 14 5.6
Hormone therapy
 Yes 152 61.0
 No 74 29.7
 Unknown 23 9.2
Stage
 0 50 20.1
 1 84 33.7
 2 69 27.7
 3 39 15.7
 Unknown 7 2.8
ER
 ER− 45 18.1
 ER+ 144 57.8
 Unknown 60 24.1
PR
 PR− 60 24.1
 PR+ 119 47.8
 Unknown 70 28.1
HER2
 HER2- 103 41.4
 HER2+ 27 10.8
 Unknown 119 47.8
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Only three of the detected cancers occurred in patients 
under fifty at the time of follow-up imaging. The median 
age of patients with recurrences detected in our study 
was 58.8 (range 44–65). The tumors recurred at a median 
of 8.6  years following diagnosis of the original cancers 
(range 2–20). Two of the cancers detected were in the 
breast remnants of patients who had undergone mastec-
tomy previously. There were two known patients (0.8%) 
in the study with documented normal MRI and mammo-
grams at our center who were known to have developed 
interval breast cancers within 6  months of screening, 
both with stage I disease.
The overall sensitivity and specificity data for MRI 
and mammography were counted for each round of 
screening, with an aggregate total calculated for all 
screening rounds (Table 4). This total includes data from 
all 571 screens included in the data set. Overall, MRI 
had a sensitivity of 84.6% (the 95% CI 54.6–98.1) and a 
specificity of 95.3 (the 95% CI 93.3–96.9). In compari-
son, mammography had a sensitivity of 23.1% (the 95% 
CI 5.0–53.8), and a specificity of 96.4% (the 95% CI 
94.5–97.8).
Discussion
Review of our institutional experience since the mid-
2000’s in screening breast cancer survivors using MRI as 
an adjunct to mammography reveals that this imaging 
modality appears to have been useful in detecting early 
in-breast recurrences and/or contralateral primaries that 
might otherwise not have been detected at this early 
stage. In total, 7 of 10, or 70%, of screen-detected early 
cancers were mammographically-occult. It is interesting 
to consider these findings in light of the lack of official 
guidelines in favor or against MRI in this; following the 
recommendation to use mammography alone may have 
potentially missed these early cancers.
There is still a paucity of published data to support the 
use of MRI in this population; however there has been 
emerging retrospective, single-institution data that sup-
ports what we found at the University of Maryland, i.e. 
that MRI tends to detect early-stage tumors that may not 
have been discovered using mammogram alone. These 
studies are reviewed below (Table  5) (Liu et  al. 2013; 
Table 2 Reason for study exclusion
Reason for study exclusion Number 
(total = 386)
Pt > 65 91
MRI done at diagnosis only 60
No mammographic correlate 56
Hx of high-risk abnormality such as LCIS/atypical  
hyperplasia only
28
Known metastatic or recurrent disease 11
BRCA1 or BRCA2 mutation carrier, Li Fraumeni 5
MRI done <11 months after initial diagnosis 4
Male patient 4
Other, including no personal breast cancer history 127
Table 3 Patient characteristics of screen detected cancers
Pt Original stage Original surgery Seen on Ipsi/Contra Stage Age at dx Age at  
recurrence
11 I Lumpectomy MRI Contralateral I 29 48
22 DCIS Lumpectomy MRI + mammo Ipsilateral II 53 65
33 I Mastectomy MRI Ipsilateral I 37 44
44 III Mastectomy MRI + mammo Contralateral I 48 52
55 DCIS Lumpectomy MRI + mammo Contralateral DCIS 57 61
66 DCIS Lumpectomy MRI Ipsilateral I 44 52
77 II Mastectomy MRI Contralateral I 47 55
88 DCIS Mastectomy MRI Ipsilateral I 44 46
99 III Lumpectomy MRI Ipsilateral DCIS 44 50
110 III Mastectomy MRI Lung metastases IV 53 63
111 III Mastectomy MRI Contralateral DCIS 46 56
Table 4 Estimated Study Parameters (total of 571 screens)
MRI MMG
Se, exact 95% CI Sp, exact 95% CI Se, exact 95% CI Sp, exact 95% CI
All screening 84.6, 54.6−98.1 95.3, 93.3−96.9 23.1, 5.0−53.8 96.4, 94.5−97.8
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Gweon et al. 2013; Geiss et al. 2013; Brennan et al. 2010). 
Reported sensitivity of MRI is 91.8 and 83.3%; reported 
specificity is 92.2 and 98% in these studies (Liu et al. 2013; 
Geiss et al. 2013), with positive predictive values (PPVs) 
ranging from as low as 27% to as high as 59.2% (Liu et al. 
2013; Gweon et al. 2013; Geiss et al. 2013; Brennan et al. 
2010).
Although there is a suggestion of benefit based on these 
experiences, and based on review of our own data, there 
is still much research to be done in the prospective set-
ting before this modality can be widely recommended. 
One of the major limitations of aggressive surveillance 
in this population that has not rigorously been assessed 
is how the early detection of breast cancers impacts sur-
vival. Women who have survived early stage breast cancer 
do have competing mortality from the original tumor for 
several years after the diagnosis. In our study the MRI-
detected breast tumors recurred at a median of 8.6 years 
following diagnosis of the original cancers (range 2–20). 
Thus it is not known if the detection of second prima-
ries or of in-breast recurrences at early stages confers the 
same long-term survival benefit as early detection of first 
cancers in unaffected women. There is limited data on the 
impact of early detection of new tumors in this cohort, 
although there is some evidence that it may have some 
impact on survival (Houssami et  al. 2009). Conversely, 
the overall 5-year mortality from breast cancer has con-
tinued to improve over recent years, making recurrences 
likely to become increasingly relevant as women live 
longer after their original diagnoses.
When comparing the use of breast MRI in this popu-
lation, it is also useful to look at the cancer detection 
rate, which in our case was 4.4%. This rate is compara-
ble to cancer detection rates in the high risk BRCA1 and 
BRCA2 mutation carrier population, for whom screen-
ing breast MRI has indeed been found to be useful and 
is an imaging modality recommended for wide usage. 
Although cross-study comparisons are not directly appli-
cable due to differences in methodologies, the breast 
cancer detection rates in prospective cohorts of BRCA 
mutation carriers was actually slightly lower than in ours, 
ranging from 0.8 to 1.6% (Kriege et al. 2006; Leach et al. 
2005; Kuhl et  al. 2005; Lehman et  al. 2005; Sardanelli 
et  al. 2011; Kuhl et  al. 2010). Additionally, in a retro-
spective study that directly compared the use of MRI in 
patients with a strong family history vs. patients with a 
personal history of breast cancer, the detection rate for 
the latter was higher (Schacht et al. 2014).
Our study has several limitations. The retrospec-
tive nature of the review of our institutional experi-
ence means that we did not control for bias in referral 
patterns and in selection of breast cancer survivors 
included in MRI surveillance; there may be inherent dif-
ferences in our patients that may modify their risk pro-
files accordingly. Additionally, while we did identify two 
instances of interval cancers that were known to have 
occurred in this cohort, there was a small proportion of 
patients who were followed at outside centers and only 
referred to our tertiary center for breast imaging. On 
these patients, definitive follow-up data was not read-
ily available and other interval cancers may have devel-
oped in these women that were not accounted for in 
our study. We also included studies done on patients 
as early as 2005. There is evidence that sensitivity of 
MRI improves over time with continued use at the 
same center, for example from 74 to 94% (P = 0.05) in 
one published experience (Passaperuma et  al. 2012); 
thus early institutional experience may be less applica-
ble than current results. Additionally, film mammogra-
phy was discontinued in favor of digital studies in early 
2008, and this may also have had an unknown effect on 
ongoing sensitivity.
We do note that almost 50% of patients included in our 
study were African-American. This is a patient popula-
tion that may be excluded from other centers’ analyses 
due to referral patterns. African-American women are 
known to have lower incidence but higher mortality from 
breast cancer than Caucasians, even when accounting 
for possible differences in access to care and in screen-
ing practices (Curtis et al. 2008; Carey et al. 2006; Stark 
et al. 2010). The inclusion of this diverse patient popula-
tion helps make our results translatable into real-world 
practices, whereas patient heterogeneity may make other 
studies’ results less applicable.
Table 5 Cancer detection using MRI in breast cancer survivors, review of the literature
a The study included mutation carriers; 7 of the 27 patients (22%) were known BRCA1 or BRCA2 mutation carriers.
Authors No. of pts Cancers/DCIS detected 
on MRI
Sensitivity Specificity PPV
Liu et al. (2013) 798 45 91.8% 92.2% 59.2%
Gweon et al. (2013) 704 10 83.3% 98% 41.7%
Geiss et al. (2013) 1,498 27a n/a n/a 27%
Brennan et al. (2010) 144 18 n/a n/a 39%
Schacht et al. (2014) 208 6 n/a n/a n/a
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Conclusion
Breast MRI as an adjunct to mammography improves 
detection of malignancy in breast cancer survivors. The 
cancer detection rate of 4.4% in our study was similar to 
the rate reported in BRCA mutation carriers, which is 
an established indication for using screening breast MRI 
as adjunct to mammography. While awaiting results of 
prospective studies in cohorts of breast cancer survivors, 
data from studies like ours may help guide management 
of patients in this population.
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